{"id":534430,"date":"2021-09-03T16:13:10","date_gmt":"2021-09-03T20:13:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/"},"modified":"2021-09-03T16:13:10","modified_gmt":"2021-09-03T20:13:10","slug":"pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/","title":{"rendered":"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company plans to issue a pre-market press release and conduct a conference call and webcast on Tuesday, September 7, 2021, to discuss interim clinical data from an ongoing Phase 2a positron emission tomography (PET) imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF).<\/p>\n

The Company will host a conference call and webcast at 8:00 a.m. ET on Tuesday, September 7th<\/sup> to discuss this update. The link to the webcast of the conference call will be posted in the Events & Presentations<\/a> section of the Company\u2019s website. The conference call may also be accessed by dialing (833) 519-1340 (domestic) or (914) 800-3902 (international) five minutes prior to the start of the call and providing the passcode 6186023. An archived replay will be accessible for 90 days following the event.<\/p>\n

\n About\u00a0Pliant Therapeutics, Inc.<\/strong>\n <\/p>\n

Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrotic and related diseases. Pliant’s lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of \u03b1v\u00df6 and \u03b1v\u00df1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting for Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small-molecule selective inhibitor of \u03b1v\u00df1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to its development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant, visit\u00a0www.pliantrx.com<\/a>\u00a0and follow us on Twitter<\/a>,\u00a0LinkedIn<\/a>,\u00a0Facebook<\/a>, and\u00a0YouTube<\/a>.<\/p>\n

\n Investor and Media Contact:<\/strong>
\n
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com<\/a>\u00a0<\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company plans to issue a pre-market press release and conduct a conference call and webcast on Tuesday, September 7, 2021, to discuss interim clinical data from an ongoing Phase 2a positron emission tomography (PET) imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The Company will host a conference call and webcast at 8:00 a.m. ET on Tuesday, September 7th to discuss this update. The link to the webcast of the conference call will be posted in the Events & Presentations section … <\/p>\n

Continue reading “Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534430","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company plans to issue a pre-market press release and conduct a conference call and webcast on Tuesday, September 7, 2021, to discuss interim clinical data from an ongoing Phase 2a positron emission tomography (PET) imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The Company will host a conference call and webcast at 8:00 a.m. ET on Tuesday, September 7th to discuss this update. The link to the webcast of the conference call will be posted in the Events & Presentations section … Continue reading "Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-03T20:13:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1MCM0Mzg4OTczIzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis\",\"datePublished\":\"2021-09-03T20:13:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/\"},\"wordCount\":366,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDI1MCM0Mzg4OTczIzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/\",\"name\":\"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDI1MCM0Mzg4OTczIzIxODU0NzY=\",\"datePublished\":\"2021-09-03T20:13:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDI1MCM0Mzg4OTczIzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDI1MCM0Mzg4OTczIzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company plans to issue a pre-market press release and conduct a conference call and webcast on Tuesday, September 7, 2021, to discuss interim clinical data from an ongoing Phase 2a positron emission tomography (PET) imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The Company will host a conference call and webcast at 8:00 a.m. ET on Tuesday, September 7th to discuss this update. The link to the webcast of the conference call will be posted in the Events & Presentations section … Continue reading \"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-03T20:13:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1MCM0Mzg4OTczIzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis","datePublished":"2021-09-03T20:13:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/"},"wordCount":366,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1MCM0Mzg4OTczIzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/","name":"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1MCM0Mzg4OTczIzIxODU0NzY=","datePublished":"2021-09-03T20:13:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1MCM0Mzg4OTczIzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1MCM0Mzg4OTczIzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-webcast-to-present-interim-clinical-data-from-ongoing-phase-2a-pet-trial-of-pln-74809-in-patients-with-idiopathic-pulmonary-fibrosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534430"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534430\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}